NOTE: This disposition is nonprecedential. 

United States Court of Appeals 

for the Federal Circuit ______________________ 

SUMITOMO PHARMA CO., LTD.,

Appellant

v.

KATHERINE K. VIDAL, UNDER SECRETARY OF 

COMMERCE FOR INTELLECTUAL PROPERTY 

AND DIRECTOR OF THE UNITED STATES 

PATENT AND TRADEMARK OFFICE,

Intervenor

______________________ 

2022-2276

______________________ 

Appeal from the United States Patent and Trademark 

Office, Patent Trial and Appeal Board in No. IPR2020-

01053.

______________________ 

Decided: April 5, 2024 

______________________ 

THOMAS SAUNDERS, Wilmer Cutler Pickering Hale and 

Dorr LLP, Washington, DC, argued for appellant. Also represented by EMILY R. WHELAN, Boston, MA; JOHN A.

DRAGSETH, SARAH JACK, MICHAEL J. KANE, Fish & Richardson P.C., Minneapolis, MN; NITIKA GUPTA FIORELLA, Wilmington, DE; TIMOTHY RAWSON, San Diego, CA.

Case: 22-2276 Document: 46 Page: 1 Filed: 04/05/2024
2 SUMITOMO PHARMA CO., LTD. v. VIDAL

 MARY L. KELLY, Office of the Solicitor, United States 

Patent and Trademark Office, Alexandria, VA, argued for 

intervenor. Also represented by PETER J. AYERS, KAKOLI 

CAPRIHAN, MAI-TRANG DUC DANG, FARHEENA YASMEEN 

RASHEED. 

______________________ 

Before TARANTO, HUGHES, and CUNNINGHAM, Circuit 

Judges.

TARANTO, Circuit Judge. 

Sumitomo Pharma Co., Ltd. (formerly Sumitomo Dainippon Pharma Co., Ltd.), owns U.S. Patent No. 9,815,827, 

titled “Agent for Treatment of Schizophrenia.” The patent 

claims detail dosing regimens for treating certain psychotic 

disorders with lurasidone1 (or a salt thereof), further specifying an absence-of-weight-gain result of following the regimens—weight gain being a recognized adverse side-effect 

of many antipsychotic drugs, J.A. 3216. Claim 1 is representative for current purposes:

1. A method for treating schizophrenia in a patient

without a clinically significant weight gain, comprising:

administering orally to the patient 

(1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzoisothiazol-3-yl)-1-piperazinylmethyl]-1-cyclohexylmethyl]-2,3-

bicyclo[2.2.1]heptanedicarboximide or a 

pharmaceutically acceptable salt thereof at 

a dose of from 20 to 120 mg/day such that 

1 There is no dispute that lurasidone is 

(1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzoisothiazol-3-yl)-1-

piperazinylmethyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboximide.

Case: 22-2276 Document: 46 Page: 2 Filed: 04/05/2024
SUMITOMO PHARMA CO., LTD. v. VIDAL 3

the patient does not experience a clinically 

significant weight gain.

’827 patent, col. 10, lines 51–59.

Slayback Pharma LLC successfully petitioned for an

inter partes review (IPR) of the ’827 patent, and the Patent 

Trial and Appeal Board eventually held all 75 claims of the 

’827 patent to be unpatentable for obviousness over a single 

prior-art reference, U.S. Patent No. 5,532,372 (Saji). Slayback Pharma LLC v. Sumitomo Dainippon Pharma Co., 

No. IPR2020-01053, 2022 WL 212259 (P.T.A.B. Jan. 20, 

2022). For present purposes, we note key aspects of the 

Board’s reasoning, without being complete even as to claim 

1, let alone the other claims also held unpatentable. 

The Board construed “a patient” (and “the patient”) to 

have its “ordinary and customary meaning of ‘one or more 

patients,’ as opposed to a ‘patient population.’” Id. at *4. 

The Board then addressed the claim limitations defining 

the required steps to be performed, finding that Saji sufficiently taught or suggested the use of lurasidone, at the 

dosages and frequencies of administration claimed in the 

’827 patent’s claims, to treat the claimed psychotic disorders. Id. at *5–9. With regard to the claimed absence-ofweight-gain property, the Board did not find that Saji (or 

any other prior-art reference) affirmatively disclosed the 

claimed result for a patient so treated, but it noted a suggestion of favorable weight-gain effects for lurasidone 

made in an article by Horisawa and others. Id. at *9–10. 

Ultimately, though, the Board concluded that the claimed 

weight-gain property was inherent in the claimed method 

of treatment, seemingly because its undisputed claim construction of “a patient” as “one or more patients” meant 

that administering lurasidone in the claimed amounts to 

even one covered patient who subsequently did not gain 

weight would meet the claim limitation and because Sumitomo acknowledged that “‘there will always be some outliers’” in side-effects in a pool of patients. Id. at *10

Case: 22-2276 Document: 46 Page: 3 Filed: 04/05/2024
4 SUMITOMO PHARMA CO., LTD. v. VIDAL

(emphasis added by the Board) (quoting Patent Owner’s 

Sur-Reply before the Board). 

After unsuccessfully seeking rehearing and a Precedential Opinion Review, Sumitomo timely appealed. Sumitomo has argued, among other things, that the Board did 

not properly consider certain safety-related evidence or the 

Horisawa suggestion and that it made an erroneous, or at 

least unclear, use of inherency doctrine in addressing at 

least the motivation-to-modify, reasonable-expectation-ofsuccess, and unexpected-results components of the obviousness analysis. Slayback did not appear on appeal, but 

the Director of the Patent and Trademark Office intervened to defend the Board’s decision. We have statutory 

jurisdiction under 35 U.S.C. § 141(c) and 28 U.S.C. 

§ 1295(a)(4)(A).

Just before oral argument, the ’827 patent expired. 

The court therefore asked about the issue of mootness at 

the outset of oral argument. Counsel for Sumitomo explained various facts, and Sumitomo’s position, relating to

the issue. Oral Arg. at 0:54–1:37.

“On appeal . . . a case becomes moot ‘when the issues 

presented are no longer “live” or the parties lack a legally 

cognizable interest in the outcome.’” ABS Global, Inc. v. 

Cytonome/ST, LLC, 984 F.3d 1017, 1020 (Fed. Cir. 2021) 

(quoting Already, LLC v. Nike, Inc., 568 U.S. 85, 91 (2013)). 

A “case remains live ‘[a]s long as the parties have a concrete interest, however small, in the outcome of the litigation.’” MOAC Mall Holdings, LLC v. Transform Holdco 

LLC, 598 U.S. 288, 295 (2023) (alteration in original) (quoting Chafin v. Chafin, 568 U.S. 165, 172 (2013)); Chafin, 568 

U.S. at 173 (“[T]he parties must continue to have a personal stake in the ultimate disposition of the lawsuit” 

(cleaned up)); cf. TransUnion LLC v. Ramirez, 594 U.S. 

413, 422–30 (2021) (ruling, in the related area of standing, 

that a case or controversy requires more than a dispute 

over a statute-based legal right—it requires a concrete 

Case: 22-2276 Document: 46 Page: 4 Filed: 04/05/2024
SUMITOMO PHARMA CO., LTD. v. VIDAL 5

interest in that right). Here, the case is moot if Sumitomo 

no longer has a concrete interest in the exclusionary right 

granted by the ’827 patent.

We conclude that Sumitomo no longer has such an interest. Given the expiration of the patent, Sumitomo has 

no interest in any forward-looking exclusion based on the 

patent. But that does not end the inquiry: As we have explained, a patentee may have a concrete interest in pursuing damages for pre-expiration infringement. See, e.g., 

Sony Corp. v. Iancu, 924 F.3d 1235, 1238–39 n.1 (Fed. Cir. 

2019). In this case, however, Sumitomo lacks any such concrete interest, as made clear in the colloquy with Sumitomo’s counsel at oral argument. 

Given the opportunity to discuss such an interest, Sumitomo expressed no interest in seeking damages for direct 

infringement from any persons who engaged in pre-expiration use of the claimed methods, including those who may 

have acquired lurasidone from a firm that had not labeled

it for a use covered by the ’827 patent’s claims. Oral Arg. 

at 0:34–0:54, 41:10–41:28. With respect to firms that 

might have sold lurasidone in a way that could have constituted indirect infringement if unlicensed—e.g., a firm 

that “jumped the gun,” “a compounding pharmacy,” Oral 

Arg. at 41:10–41:27—Sumitomo noted that there was only 

a theoretical possibility that such firms even existed: Sumitomo did not affirmatively conjecture that there were 

any such firms. Oral Arg. at 41:27–41:39. To the contrary, 

it stated that, as far as it knew, the only firms marketing 

lurasidone with relevant instructions were firms already 

under license to Sumitomo, pursuant to settlement agreements with it. See Oral Arg. at 0:33–0:41. It made clear, 

moreover, that, in contrast to what would often be true in 

different kinds of markets, it was very unlikely that there

were such unlicensed firms unknown to it, given the regulatory entry and other requirements in this area. See Oral 

Arg. at 0:28–0:34, 0:42–0:54, 1:04–1:12, 41:10–41:39. The 

existence of such firms, in this case, presents only “a 

Case: 22-2276 Document: 46 Page: 5 Filed: 04/05/2024
6 SUMITOMO PHARMA CO., LTD. v. VIDAL

hypothetical state of facts,” which is not enough to prevent 

mootness. Chafin, 568 U.S. at 173. 

Those statements, together with Sumitomo’s focus only 

on its concern with the Board’s reasoning, Oral Arg. at 

41:40–41:50, and its representation that it would not oppose vacatur on mootness grounds, Oral Arg. at 41:51–

42:04, indicate that Sumitomo now lacks a legally cognizable interest in the validity of the ’827 patent before its expiration. These special circumstances properly distinguish 

this case from Sony Corp. v. Iancu, which was not a pharmaceutical case and which recited no reason even to doubt 

the reality of the possibility of pre-expiration damages, 

much less to be confident that such a possibility was not a 

real one. See 924 F.3d at 1237, 1238–39 n.1. We conclude 

that the expiration of the patent has extinguished any concrete stake Sumitomo has in a reversal on the merits of the 

patentability ruling. The case before us is therefore moot.

The Supreme Court, relying on United States v. Munsingwear, Inc., 340 U.S. 36, 39 (1950), has explained that, 

in cases coming from district courts, its “‘ordinary practice 

in disposing of a case that has become moot on appeal is to 

vacate the judgment with directions to dismiss.’” New York 

State Rifle & Pistol Association v. City of New York, 140 S. 

Ct. 1525, 1526 (2020) (quoting Lewis v. Continental Bank 

Corp., 494 U.S. 472, 482 (1990)); accord Azar v. Garza, 584 

U.S. 726, 729 (2018); Arizonans for Official English v. Arizona, 520 U.S. 43, 71 (1997). In a case involving Munsingwear in the context of a Board order, the Supreme 

Court ordered vacatur, but was silent about dismissal of 

the Board proceeding. PNC Bank National Association v. 

Secure Axcess, LLC, 584 U.S. 974 (2018). We have sometimes included the direction-to-dismiss aspect of the Munsingwear practice even when the appeal to us came from a 

non-Article III forum. See INVT SPE LLC v. International 

Trade Commission, 46 F.4th 1361, 1370 (Fed. Cir. 2022);

Apple Inc. v. Voip-Pal.com, Inc., 976 F.3d 1316, 1321 (Fed. 

Case: 22-2276 Document: 46 Page: 6 Filed: 04/05/2024
SUMITOMO PHARMA CO., LTD. v. VIDAL 7

Cir. 2020) (from PTAB); Tessera, Inc. v. International 

Trade Commission, 646 F.3d 1357, 1371 (Fed. Cir. 2011). 

Here, we deem it appropriate to vacate the Board order 

in this matter, considering the “conditions and circumstances” that can bear on application of the “equity” practice of vacatur. Azar, 584 U.S. at 729 (internal quotation 

omitted); see Acheson Hotels, LLC v. Laufer, 601 U.S. 1, 14–

16 (2023) (Jackson, J., concurring) (calling for case-specific 

assessment of vacatur). Mootness occurred here “through 

happenstance—circumstances not attributable to the parties,” so this case does not involve mootness caused by voluntary action such as settlement, and vacatur pursuant to 

the ordinary Munsingwear practice “is in order” here. Arizonans for Official English, 520 U.S. at 71–72 (distinguishing mootness by settlement); see also Azar, 584 U.S. at 729

(mootness by unilateral action). Moreover, even if insubstantiality of the grounds of an appeal might in some cases 

weigh against vacatur, this is not such a case: Although we 

do not decide whether Sumitomo is ultimately correct in 

any of its grounds for seeking to set aside the Board’s decision, we conclude that at least some of those grounds are 

substantial. We include the direction to dismiss in this 

case, reserving for another case a full consideration of the 

issue of when such a direction might be inappropriate in a 

case coming from the Board. 

For the foregoing reasons, the decision of the Board is 

vacated, and the case is remanded for the Board to dismiss 

the IPR.

The parties shall bear their own costs.

VACATED AND REMANDED

Case: 22-2276 Document: 46 Page: 7 Filed: 04/05/2024